Erlotinib in the treatment of advanced pancreatic cancer - Wikidata - awgldk - TriplyDB

Erlotinib in the treatment of advanced pancreatic cancer

Erlotinib in the treatment of advanced pancreatic cancer

http://www.wikidata.org/entity/Q37307567

about

Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly Biomarkers and Targeted Therapy in Pancreatic Cancer Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?Efficacy of minimally invasive therapies on unresectable pancreatic cancer.EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options.Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics.CONCORD biomarker prediction for novel drug introduction to different cancer types.A microfluidics platform for combinatorial drug screening on cancer biopsies.Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

P2860

Q24297412-68D5D5E1-5C59-4217-AF94-C01788BCB80C Q26752755-B3A17C56-0816-450A-B56C-7C2AA0674A07 Q28074614-B609743D-D64D-4FA0-9D04-DFABC19E5CB4 Q30367429-540FA313-7A5E-4DBD-AF6B-A65B63074A79 Q33556577-BBBC48C0-CC79-4029-8279-85137ECFE316 Q33754779-5C9CF0C5-A79F-4DEE-854F-3B730494AEFE Q34569071-4761612D-6C8D-459F-A081-068AB4E304F8 Q35623056-B95A6F6A-8F65-4C46-B613-90431B0E187D Q36571455-DA28D4B2-C892-48B9-B150-776579CE7377 Q37061902-C73CC8FF-A8C0-4AAF-B955-765FA39F108D Q37193103-77FDB5D4-2176-4A34-9EEF-3888F1E7951A Q37265792-4894E455-6126-4B4A-A642-99A4BEE379BE Q37354138-A6F84016-4538-47BA-B655-C776D87A6EE9 Q37561771-F10D39B9-C49B-488E-9714-0AD741E9727B Q37742975-49F537CF-A025-4910-B279-73F3E0569708 Q38040121-A920350D-D875-40F2-AC51-411739150673 Q38844551-2C97EA89-A005-48B5-A9C6-9D46B68572B6 Q49167162-44BD4AC6-7916-4484-A3E3-682E29C7FD31 Q50128212-AD648204-751D-414C-B535-B0D52BB5E3BA Q55363674-3036DB5A-D7BA-4740-99F8-E48735DB4AB0 Q58706536-D6A4FD16-80A5-4935-A160-AEF9DE179EAC

P2860

Erlotinib in the treatment of advanced pancreatic cancer

http://www.wikidata.org/entity/Q37307567

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Erlotinib in the treatment of advanced pancreatic cancer

@en

Erlotinib in the treatment of advanced pancreatic cancer.

@nl

type

label

Erlotinib in the treatment of advanced pancreatic cancer

@en

Erlotinib in the treatment of advanced pancreatic cancer.

@nl

prefLabel

Erlotinib in the treatment of advanced pancreatic cancer

@en

Erlotinib in the treatment of advanced pancreatic cancer.

@nl

P1433

Q37307567-A3ABA007-B549-4101-98B6-99E2F7E51582

P1476

Q37307567-64AB12E2-28F7-4ADE-B448-CF5DC846C414

P2093

Q37307567-0B657B57-4944-498D-92DE-2836918C794B

Q37307567-55663878-3A01-4FB1-8E18-85BB5D77EA2C

P2860

Q37307567-03FDA66D-289C-45D4-BB0E-DAB7BAA98AD1

Q37307567-04232D4E-386F-42EC-90A3-B637D8DDC2DF

Q37307567-05F8D1E5-2822-48DD-B77D-F2352CB122F8

Q37307567-06835F9C-1882-4E03-9CC6-E0350EE97746

Q37307567-0BDE66EB-A98B-4313-8B22-30ADF7B31747

Q37307567-0E72D4DD-072B-4BCA-8EDC-66F7C24AB6EA

Q37307567-18999464-E47B-4F0C-AEFB-55C2E2CBE88D

Q37307567-19E8D3BB-15D1-4D6D-9CFE-C9C4C4779B21

Q37307567-25183116-4225-4840-BA34-84B75F2B1F65

Q37307567-33DA1B12-E01E-454D-8ECE-4C4404BCEA78

P304

Q37307567-13FD0F1B-C7E1-4130-A806-95F90B50AEDF

P31

Q37307567-9E5DC153-3332-4AAB-9291-186017D6DAE7

P356

Q37307567-FA56EDE8-69EB-402D-BC3E-BFF395F39407

P433

Q37307567-691F46A1-9A7E-4185-8ED4-5BFF20F925B3

P478

Q37307567-DFAF6D32-4B80-4056-BFE2-C59163251481

P577

Q37307567-B5977A48-ED5F-4DB5-9DD1-C122A41349DF

P698

Q37307567-17B76F52-1909-430F-81F8-5E5005C1E074

P932

Q37307567-EABC6E4A-47F8-4D06-AF0A-29FA42BC2E0D

P356

P1433

Biologics: Targets and Therapy

P1476

Erlotinib in the treatment of advanced pancreatic cancer

@en

P2093

Andrew H Ko

http://www.w3.org/2001/XMLSchema#string

Robin K Kelley

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Untangling the ErbB signalling network

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions

Cancer statistics, 2007

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer.

P304

83-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S1832

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19707431

http://www.w3.org/2001/XMLSchema#string

P932

2727779

http://www.w3.org/2001/XMLSchema#string